The efficacy and
safety of omarigliptin, once a week drug in type 2 diabetes treatment was
compared with a daily dose of sitagliptin drug.

The study
results found 25mg of omarigliptin drug once a week to be an appropriate dose
for treatment.

The efficacy and safety
of a once-week diabetes drug omarigliptin in patients with type 2 diabetes
were compared with the daily drug sitagliptin by a research team from the LMC
Diabetes & Endocrinology, Toronto, Ontario, Canada.

The research findings
were published in the journal Diabetes, Obesity and Metabolism.

Dipeptidyl peptidase-4
(DPP-4) inhibitors or gliptins is a class of drugs, which
can be prescribed for the treatment of type 2 diabetes.

‘Weekly diabetes drug omarigliptin found to produce similar benefits as that of sitagliptin drug.’

Type 2 diabetes is the most
common form of diabetes that causes elevated blood sugar levels. According to
the World Health Organization statistics, the number of people with diabetes
increased to 422 million in 2014.

Research Study

The research study was
conducted on type 2 diabetes mellitus patients who took metformin drug
for treatment. These patients had the HbA1c level between 6.5-9.0% while
screening and had a fasting blood glucose level greater than 7.2 and less than
14.4mmol/liter at randomization.

The research study was
conducted at 97 sites in 13 countries that include 6 in Argentina, 6 in Canada,
1 in Croatia, 5 in Estonia, 5 in Georgia, 10 in Hungary, 4 in Israel, 5 in
Malaysia, 4 in the Philippines, 9 in Poland, 8 in Romania, 8 in South Africa
and 26 in the USA.

A 1- week screening
period, followed by a 2- week single placebo run-in period and 24-week
treatment period was carried out.

After the placebo (dummy
pill which has no active ingredient) period, a 1:1 ratio of either a 25mg of
omarigliptin drug was given once weekly with a placebo matching sitagliptin for
once daily or 100mg of sitagliptin every day with a placebo weekly dose of
omarigliptin.

Findings of the Study

The study evaluated the
efficacy, safety, tolerability of omarigliptin drug for 24 weeks.The percentage
of patients who received HbA1c levels of less than 7.0% and less than 6.5% were
evaluated.

The study results found

Patients who took an additional
once weekly omarigliptin drug 25mg had similar reductions in HbA1c level and
fasting blood glucose levels when compared to a daily dose of 100mg sitagliptin.

The efficacy of controlling the blood glucose
levels with DPP-4 drug inhibitors over a period of one week is found to be
similar to that of daily administration.

The results also
confirm that 25mg of omarigliptin drug is an appropriate dose to achieve
effective treatment for type2 diabetes .

Omarigliptin Drug

It is a dipeptidyl
peptidase-4 enzyme inhibitor drug which acts by regulating the incretin
hormones including glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP). These hormones are involved in the
physiological regulation of glucose levels.

The adverse effects of
Omarigliptin drug were well tolerated and the incidence of patients reporting
low blood sugar levels (hypoglycemia) was also similar with the sitagliptin
group.

The drug was
recently approved in Japan as a single weekly dose for diabetes treatment.

Follow Us On :

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer